Skip to content

Psychedelic-assisted therapy: all studies

Page 184 of 294: studies 1,831 to 1,840 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.

Molecular biotechnology 2025 Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram et al. 2 citations

Depression, a global health concern with significant implications for suicide rates, remains challenging to treat effectively with conventional pharmacological options. The existing pharmaceutical interventions for these illnesses need daily dosing, are accompanied by various adverse effects, and may exhibit limited efficacy in certain cases. However, hope emerges from an unlikely...

DOI: 10.1007/s12033-023-00994-7 (opens in new tab) Full text (opens in new tab) Disorder Mushroom Psilocybin therapy Mental health treatment +3

Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour.

Neuropharmacology 2025 James J Gattuso, Carey Wilson, Anthony J. Hannan et al. 10 citations

Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent as compulsive disorders require research into new pharmacological treatment options as the current frontline treatments such as selective serotonin reuptake inhibitors, require chronic administration, have significant side effects, and leave almost half of the...

DOI: 10.1016/j.neuropharm.2024.110202 (opens in new tab) Full text (opens in new tab) Anxiety Psilocybin magic mushrooms Hallucinogens Psychedelics +5

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...

DOI: 10.1176/appi.ajp.20230890 (opens in new tab) 5-MEO-DMT Depression Psychedelic drugs Quick-onset treatment +3

Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2025 Ines Erkizia-Santamaría, Igor Horrillo, J. Javier Meana et al. 10 citations

In the rapidly growing field of psychedelic research, psilocybin (and active metabolite psilocin) has been proposed as a promising candidate in the search for novel treatments for neuropsychiatric disorders. Clinical trials have revealed that psilocybin has a large, rapid, and persistent effect in the improvement of symptoms of depression and anxiety. The safety profile is considered...

DOI: 10.1016/j.pnpbp.2025.111249 (opens in new tab) Psilocybin Antidepressant Psychotherapist Narrative

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

European Psychiatry 2025 Marianne Destoop, Pavel Mohr, Florence Butlen-Ducuing et al. 7 citations

Abstract Background Recent years show an exponential increased interest (“renaissance”) in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of...

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder.

Journal of Pharmacology and Experimental Therapeutics 2025 Claire E Miller, Phillip R. Zoladz 10 citations

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals with this condition experience numerous physiological and behavioral alterations, including intrusive memories, avoidance of trauma-related stimuli, heightened anxiety, hypervigilance, impaired cognition, elevated resting heart rate and blood pressure,...

Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.

Cureus 2025 Sorcha O'Connor, Kate Godfrey, Sara Reed et al. correction

Background: Obsessive-compulsive disorder (OCD) is a complex condition marked by persistent distressing thoughts and repetitive behaviours. Despite its prevalence, the mechanisms behind OCD remain elusive, and current treatments are limited. This protocol outlines an investigative study for individuals with OCD, exploring the potential of psilocybin to improve key components of cognition...

DOI: 10.7759/cureus.c209 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Clinical research OCD

On the varieties of conscious experiences: Altered Beliefs Under Psychedelics (ALBUS).

Neuroscience of Consciousness 2025 Adam Safron, Arthur Juliani, Nicco Reggente et al. 44 citations

How is it that psychedelics so profoundly impact brain and mind? According to the model of "Relaxed Beliefs Under Psychedelics" (REBUS), 5-HT2a agonism is thought to help relax prior expectations, thus making room for new perspectives and patterns. Here, we introduce an alternative (but largely compatible) perspective, proposing that REBUS effects may primarily correspond to a particular (but...

DOI: 10.1093/nc/niae038 (opens in new tab) Full text (opens in new tab) Neuroplasticity Consciousness-states Default-mode-network Belief-systems +4

Is there a place for psychedelics in sports practice?

Acta Neuropsychiatrica 2025 Isabel Werle, Marina A. M. Portes, Leandro J Bertoglio 2 citations

Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use disorder, offering relatively safe profiles, enhanced efficacy, and lasting effects after a few applications. Athletes often experience high levels of stress and pressure, making them susceptible to these psychiatric conditions. However, the effects...

Tripping on Utopia: Margaret Mead, the Cold War and the Troubled Birth of Psychedelic Scienceby Benjamin Breen, New York: Grand Central Publishing. 2024. pp. 369. $3000 (cloth). ISBN 9781538722374

Journal of the History of the Behavioral Sciences December 25, 2024 Rob Schraff

A kaleidoscopic narrative of the history of not only psychedelic science, but also an extraordinary network of behavioral scientists cultivated by Margaret Mead that had a profound impact on the history of the 20th century, Benjamin Breen's Tripping on Utopia: Margaret Mead, the Cold War and the Troubled Birth of Psychiatric Science will prove deeply fascinating to historians, behavioral...

DOI: 10.1002/jhbs.70012 (opens in new tab) Consciousness Utopia Modernity Art history +5